Mylan acquires Central/Eastern Europe generics business from Merck

PITTSBURGH Mylan has acquired Merck’s Central and Eastern Europe generics businesses, which include operations in Poland, Hungary, Slovakia, Slovenia and Czech Republic.

This acquisition is part of the October 2007 agreement between the two companies where Mylan acquired Merck’s generic businesses in Western Europe, Asia-Pacific, Africa and North America. Mylan exercised its option to get the units in Central and Eastern Europe.

“Our acquisition of the Central Eastern Europe businesses gives us access to an additional area with significant growth opportunities for generics,” said Mylan vice chairman and chief executive officer Robert J. Coury. “It reflects our global strategy to leverage existing platforms, rather than create start-up organizations. In that respect, we believe the CEE businesses will benefit significantly from Mylan’s scale, vertical and horizontal integration, and robust product portfolio.”